Adavivint

• Description :

  Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells[1].

• Product Name Alternative :

  SM04690; Lorecivivint

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Wnt

• Type :

  Reference compound

• Related Pathways :

  Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Adavivint.html

• Purity :

  98.85

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

• Smiles :

  CC(C)CC(NC1=CC(C2=CC3=C(NN=C3C(N4)=NC5=C4C(C6=CC=CC(F)=C6)=CN=C5)C=C2)=CN=C1)=O

• Molecular Formula :

  C29H24FN7O

• Molecular Weight :

  505.55

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26 (1) :18-27.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [1467093-03-3]